The Quantum Truth Map for Real World Applications in Life Sciences is a workshop that navigates quantum’s evolution from today to 2035, focusing on when and how it will impact the life sciences industry. Attendees will see a realistic development timeline, identify high-value applications, and leave with a clearer view of quantum’s role in their business ready to return to their workplaces with actionable steps
Key Takeaways
- Clarity on the Timeline – Understand when quantum will deliver real capabilities for life sciences.
- Relevant Use Cases – Identify the most promising applications for your organization.
- Team Alignment – Leave with focus areas to guide internal discussions and planning.
Richard Sear
Managing Partner
Everest Group
Richard Sear
Managing Partner
Everest Group
Dawid Sierzant
Partner
SDP Legal
Mariusz Kondrat
Managing Partner
Kondrat & Partners
Evelina Kurgonaite
Secretary General
Fair Standards Alliance
A roundtable discussion across payers, providers, and employer groups. This discussion will focus on patients dealing with hot flashes and moderate to severe vasomotor symptoms (VMS) and sleep disturbances, which negatively impact women’s quality of life, where there is an unmet need for effective therapies.
Bayer
Website: https://www.bayer.com/en/
Bayer is a recognized leader in the area of women’s healthcare, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide. Today, Bayer’s research and development efforts focus on finding new treatment options for menopause as well as gynecological diseases and includes several compounds in various stages of pre-clinical and clinical development. Together, these projects reflect the company’s approach to research, which prioritizes targets and pathways with the potential to alter the way that gynecological diseases are treated. Additionally, Bayer intends to provide 100 million women in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations.
